Rebound Growth for One in Four With Infantile Hemangioma

Share this content:
Rebound Growth for One in Four With Infantile Hemangioma
Rebound Growth for One in Four With Infantile Hemangioma

FRIDAY, March 11, 2016 (HealthDay News) -- About 25 percent of patients with infantile hemangioma (IH) have rebound growth, according to a study published online March 7 in Pediatrics.

Sonal D. Shah, M.D., from the University of California at San Francisco, and colleagues conducted a multicenter retrospective cohort study involving propranolol-treated patients with IHs. They obtained patient demographic characteristics, IH characteristics, and specifics of propranolol therapy for 912 patients.

The researchers found that 25.3 percent of patients had rebound growth, with initial rebound occurring at a mean age of 17.1 months. Compared with those who discontinued therapy at 12 to 15 months, the odds of rebound were increased among those who discontinued therapy at younger than 9 months (odds ratio, 2.4). In univariate analysis, female gender, location on head and neck, segmental pattern, and deep or mixed skin involvement correlated with rebound. Only deep IHs and female gender were significantly associated with rebound on multivariate analysis (odds ratios, 3.3 and 1.7, respectively). Eighty-three percent of those with rebound growth required therapeutic modification, including 62 percent of patients with modification in their propranolol therapy.

"Predictive factors for rebound growth included age of discontinuation, deep IH component, and female gender," the authors write. "Patients with these predictive factors may require a prolonged course of therapy."

Two authors disclosed financial ties to Pierre Fabre Dermatology.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths